Members are advised of changes and updates to the Pharmaceutical Benefits Scheme. Several changes to the Pharmaceutical ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment ...

Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Powered by a proprietary ADC platform, Oqory is focused on delivering therapies that improve outcomes for patients with ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...